Findings {#Sec1}
========

CD4^+^ T-cells are targets for infection by human immunodeficiency virus type 1 (HIV-1), whereby latent, replication-competent provirus can persist despite suppressive antiretroviral therapies \[[@CR1]\]. Following exposure to antigen, naïve CD4^+^ T-cells (T~N~) proliferate and differentiate into antigen-specific effector cells or self-renewing memory T-cells \[[@CR2],[@CR3]\]. Memory CD4^+^ T-cell subsets include long-lived central memory T-cells (T~CM~), transitional memory (T~TM~) and shorter-lived effector memory T-cells (T~EM~) \[[@CR4],[@CR5]\]. Recently, a new memory T-cell subset was described in CD4^+^ and CD8^+^ T-cell populations in humans \[[@CR6]-[@CR8]\]. These cells, termed stem cell memory T cells (T~SCM~), account for approximately 2--4% of the CD4^+^ T-cell population in HIV-seronegative individuals, and are the longest-lived memory CD4^+^ T-cell subset \[[@CR8],[@CR9]\]. Importantly, T~SCM~ contribute to the persistent cellular HIV-1 reservoir \[[@CR6]\].

HIV-1 entry into cells is mediated by the interaction between the viral envelope protein complex (Env) and cell-surface CD4, and then with a chemokine coreceptor, either CCR5 or CXCR4 (reviewed in \[[@CR10]\]). The ability of HIV-1 to engage CCR5, CXCR4 or either coreceptor for entry is a major determinant of cellular tropism, and is used to classify viruses as R5, X4 or R5X4, respectively \[[@CR11]\].

Although HIV-1 subtype C (C-HIV) strains account for \>50% of HIV-1 infections worldwide and exhibit pathogenicity and tropism alterations that are distinct from other HIV-1 subtypes \[[@CR12]\], at present there are few studies describing the susceptibility of CD4^+^ T-cell subsets to infection by clinical R5 C-HIV strains, and none concerning clinical X4 C-HIV isolates. Given recent reports that have described increased incidence of X4 C-HIV strains across multiple cohorts, particularly from patients with late-stage disease (up to 52%) \[[@CR12]-[@CR17]\], this lack of knowledge has implications for HIV/AIDS cure strategies, including the widely discussed use of histone deacetylase inhibitors to activate transcription of latent provirus and purge CD4^+^ memory T-cell reservoirs.

Since changes in HIV-1 cellular tropism may influence the size and composition of viral reservoirs, here we sought to quantify and compare the susceptibility of naïve and memory CD4^+^ T-cell subsets, including T~SCM~, to infection by clinical X4 and R5 C-HIV strains from patients who either maintained R5 viruses or experienced emergence of X4 strains during progression from chronic to advanced stages of C-HIV infection.

Experimental procedures {#Sec2}
-----------------------

We utilized X4 (n = 2) and R5 (n = 15) Envs cloned from longitudinal plasma samples of three treatment-naïve C-HIV infected subjects (1503, 1854 and 1109) from the recently described MUSH cohort \[[@CR12]\] who, over a 3-year sampling period, showed clinical and immunological evidence of progression from chronic to advanced stages of infection \[[@CR12],[@CR17]\] (Table [1](#Tab1){ref-type="table"}). Subjects 1503 and 1854 exclusively harboured R5 viruses in plasma samples provided at enrolment (E), 1-year later (I; intermediate) and 3-years after enrolment (F; final), whereas subject 1109 experienced a switch from dominant R5 viruses in enrolment and intermediate plasma samples to dominant X4 strains in the final plasma sample \[[@CR12]\] (Table [1](#Tab1){ref-type="table"}).Table 1**Subject 1503, 1854 and 1109 EnvsSubjectPlasma sampleCD4** ^**+**^ **T-cell count (cells/μL)Viral Load (RNA copies/ml)Env IDCoreceptor usage1503**E3965.7311R513R5I1685.697R511R5F2595.717R58R5**1854**E4355.618R510R5I2796.574R520R5F2725.674R58R5**1109**E3675.5410R542R5I4025.593R5F1695.6730X439X4\-\--F-30-E10V3R5The CD4^+^ T-cell counts and plasma viral loads for these subjects have been reported previously, and are summarized again here to assist in the interpretation of the CD4^+^ T-cell subset tropism data \[[@CR12]\]. Plasma viral load values are shown as log~10~. Envs were cloned directly from plasma samples provided at enrolment (E), 1-year later (I; intermediate) and 3-years after enrolment (F; final). Env coreceptor usage was determined by infecting NP2 or U87 cells expressing CD4 and either CCR5 or CXCR4 with Env-pseudotyped luciferase reporter viruses \[[@CR12]\]. The 1109-F-30-E10V3 Env was generated by mutating 1109-F-30 to express the V3 region of 1109-E-10 \[[@CR12],[@CR17]\]. Env ID, HIV-1 Env identification number as described in \[[@CR12]\].

To determine the CD4^+^ T-cell subset tropism for each of these Envs, we utilized an *in vitro* multi-parameter flow cytometry-based infection assay, described in our recent studies \[[@CR18],[@CR19]\] and in Additional file [1](#MOESM1){ref-type="media"}. Briefly, peripheral blood CD4^+^ T-cells isolated from four HIV-seronegative donors were infected with single-round Env-pseudotyped GFP reporter viruses, then HIV-1 infection was determined by GFP positivity and the distribution of infection among CD4^+^ T-cell subsets was determined using antibodies specific for cell-surface markers; T~N~ (CD45RO^−^CCR7^+^CD27^+^), T~SCM~ (CD45RO^−^CCR7^+^CD27^+^CD95^+^CD122^+^), T~CM~ (CD45RO^+^CCR7^+^CD27^+^), T~TM~ (CD45RO^+^CCR7^−^CD27^+^), T~EM~ (CD45RO^+^CCR7^−^CD27^−^) and T~EMRA~ (CD45RO^−^CCR7^−^CD27^−^) The fluorochrome labeled flow cytometry antibodies used in this study are described in Additional file [1](#MOESM1){ref-type="media"}: Table S1. Our T-cell subset gating strategy, which we have described previously \[[@CR18]\], is illustrated in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

GFP reporter viruses pseudotyped with well-characterized T-cell tropic B-HIV Envs JR-CSF (R5), HXB2 (X4) and Macs1-Spleen12 (R5X4) were used as controls \[[@CR19]-[@CR22]\]. CD4^+^ T-cells were infected with 3000 infectious units of B- and C-HIV R5 viruses, and 1250 infectious units of B- and C-HIV R5X4 and X4 viruses, which we determined here (data not shown) and previously \[[@CR18],[@CR19]\] to be virus inoculums that ensure infections within the linear range.

R5 and X4 C-HIV Envs exhibit alternative CD4^+^ T-cell subset tropism profiles {#Sec3}
------------------------------------------------------------------------------

Prior to infection we first showed that the proportion of each CD4^+^ T-cell subset (Additional file [1](#MOESM1){ref-type="media"}: Figure S2) and the proportion of cells expressing CCR5 and CXCR4 (Additional file [1](#MOESM1){ref-type="media"}: Table S2) was similar between donors, and was consistent with the findings of previous studies \[[@CR10],[@CR18],[@CR19],[@CR23],[@CR24]\]. R5 C-HIV Envs mediated levels of CD4^+^ T-cell infection (mean 1% ± standard deviation 0.4% of infected CD4^+^ T-cells) similar to JR-CSF (1 ± 0.1%), and preferentially infected memory T-cells; T~N~ (21.5 ± 8.9%), T~SCM~ (3.3 ± 2.6%), T~CM~ (24.7 ± 5.3%), T~TM~ (20.1 ± 4.7%), T~EM~ (14.9 ± 4.8%) and T~EMRA~ (0.6 ± 0.4%) (Figure [1](#Fig1){ref-type="fig"}a). X4 C-HIV Envs mediated levels of CD4^+^ T-cell infection (3.5 ± 1.8%) similar to HXB2 (1.7 ± 0.9%), and preferentially infected naïve T-cells; T~N~ (62.1 ± 12.1%), T~SCM~ (1.1 ± 1.7%), T~CM~ (16.9 ± 7.3%), T~TM~ (13.5 ± 4.6%), T~EM~ (5.7 ± 2.8%) and T~EMRA~ (0.6 ± 0.7%), (Figure [1](#Fig1){ref-type="fig"}a). The preferential infection of memory and naive T-cells by R5 and X4 C-HIV Envs, respectively, could be influenced by the variation in the proportion of cells that express CCR5 and CXCR4 (Additional file [1](#MOESM1){ref-type="media"}: Table S2) as CD45RO^−^ cells had a higher proportion of CD4^+^ T-cells expressing CXCR4 compared to CD45RO^+^ cells, which had higher proportions of CD4^+^ T-cells expressing CCR5. Together, these data suggest that, within these subjects, C-HIV tropism for CD4^+^ memory and naïve T-cells is constrained by Env coreceptor specificity.Figure 1**Proportion of CD4** ^**+**^ **T-cell subsets infected by Env-pseudotyped GFP reporter viruses. (a)** Values represent the percentage of infected CD4^+^ T-cells that belong to the indicated subset; naïve (T~N~, dark blue), stem cell memory (T~SCM~, red), central memory (T~CM~, yellow), transitional memory (T~TM~, light blue), effector memory (T~EM~, purple) and effector memory RA (T~EMRA~, green). Values were averaged across four HIV-seronegative donors. Error bars represent the standard deviation. CD4^+^ T-cells were infected with GFP reporter viruses pseudotyped with (i) subtype C HIV-1 Envs isolated from plasma samples of subjects 1503, 1854 and 1109 provided at enrolment (E), 1-year later (I; intermediate) and 3-years after enrolment (F; final), or (ii) subtype B HIV-1 control Envs. Text in parentheses indicates the number of Envs isolated per plasma sample and/or Env coreceptor usage; CCR5-specific (R5), CXCR4-specific (X4), uses CCR5 or CXCR4 (R5X4). **(b)** Values represent the percentage of infected CD4^+^ T-cells that are T~SCM~ for each Env-pseudotyped GFP reporter virus per donor (individual dots). Columns display the mean and standard deviation. Statistical analyses were performed using Mann Whitney tests, p-values ≤0.05 were considered significant.

Env determinants underlying the linkage between C-HIV coreceptor specificity and CD4^+^ T-cell tropism alterations {#Sec4}
------------------------------------------------------------------------------------------------------------------

To better understand the underlying Env determinants of C-HIV tropism for CD4^+^ T-cell subsets, we quantified the susceptibility of CD4^+^ T-cells isolated from peripheral blood of four HIV-seronegative donors to infection by GFP reporter viruses pseudotyped with X4 1109-F-30 Env that was mutated to express the V3 region of the R5 1109-E-10 Env (referred to as 1109-F-30-E10V3) (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Previously we utilized this Env to define the critical C-HIV V3 alterations necessary to confer CXCR4 usage \[[@CR12],[@CR18]\]. In these studies, we confirmed that either an Ile314-Gly315 insertion or an Arg318Pro alteration in the V3 loop crown (GPGQ) motif was sufficient to confer an R5X4 phenotype, and that both of these alterations together conferred a strictly X4 phenotype. Here, the R5 1109-F-30-E10V3 Env displayed a CD4^+^ T-cell subset tropism profile that was similar to enrolment and intermediate 1109 R5 Envs, preferentially infecting memory CD4^+^ T-cells; T~N~ (30.9 ± 17.2%), T~SCM~ (2.1 ± 3.6%), T~CM~ (26.4 ± 6.5%), T~TM~ (24.4 ± 7.1%), T~EM~ (15.9 ± 5.2%) and T~EMRA~ (0.4 ± 0.4%) (Figure [1](#Fig1){ref-type="fig"}a). These findings establish (i) the V3 loop as a key determinant of CD4^+^ T-cell subset tropism for viruses from subject 1109, and (ii) the linkage between C-HIV coreceptor specificity and CD4^+^ T-cell tropism alterations.

V3 determinants of 1109-F-30 tropism for CD4^+^ T-cell subsets are shared by the majority of CXCR4-using C-HIV Envs {#Sec5}
-------------------------------------------------------------------------------------------------------------------

Our analyses of X4 C-HIV Envs were limited to just subject 1109 because this was the only individual within our longitudinal cohort to experience the emergence of CXCR4-using strains \[[@CR12]\]. To gauge the likelihood that our findings would translate to other CXCR4-using C-HIV strains, we analyzed every previously published R5 (n = 1653) and CXCR4-using (n = 203) C-HIV Env sequence for expression of the defined 1109-F-30 V3 determinants of CXCR4-usage and tropism for CD4^+^ T-cell subsets, namely the two amino acid insertion at positions 314--315 and/or the GPGQ crown alteration. Additional file [1](#MOESM1){ref-type="media"}: Table S4 shows that of the CXCR4-using V3 sequences, 27.1% contained a 314--315 insertion, of which 81.9% contained Ile314-Gly315 (36.5% overall), 62.6% exhibited a GPGQ alteration, of which 55.1% exhibited GRGQ (58.1% overall), and 23.2% contained both a 314--315 insertion and a GPGQ alteration, of which 84.9% exhibited both Ile314-Gly315 and GRGQ (32.4% overall). These proportions were even higher when assessing just strictly X4 C-HIV Envs, where 44.6% contained a 314--315 insertion, of which 81.8% contained Ile314-Gly315 (36.5% overall), 83.8% exhibited a GPGQ alteration, of which 69.3% exhibited GRGQ (58.1% overall), and 39.2% contained both a 314--315 insertion and a GPGQ alteration, of which 82.7% exhibited both Ile314-Gly315 and GRGQ (32.4% overall). Conversely, none of the R5 V3 sequences contained a 314--315 insertion and only 1.9% exhibited a GPGQ alteration (none of which were GRGQ). Although further functional studies are required to establish the CD4+ T-cell subset tropism properties of diverse CXCR4-using C-HIV strains, these sequence analyses suggest that a substantial proportion of previously reported X4 C-HIV Envs will likely exhibit a similar profile to that of the X4 Envs from subject 1109.

T~SCM~ are susceptible to infection by CCR5- and CXCR4-using clinical C-HIV viruses {#Sec6}
-----------------------------------------------------------------------------------

Recently, a new subset of CD4^+^ T-cells, T~SCM~, was found to contribute significantly to the viral reservoir during HIV-1 disease progression \[[@CR6]\]. Here, we found that the proportion of CD4^+^ T-cells infected by X4 C-HIV Envs from subject 1109 that were T~SCM~ (1 ± 1.4%) was significantly less (by Mann Whitney test) than that of R5 C-HIV strains from subject 1109 (3.7 ± 2.9%, p = 0.0165), 1503 (2.6 ± 2.6%, p = 0.0354) and 1854 (3.8 ± 2.4%, p = 0.0013) (Figure [1](#Fig1){ref-type="fig"}b). Unexpectedly, the proportion of T~SCM~ infected by the R5 1109-F-30-E10V3 Env (1.9 ± 3.2%) was statistically similar to both R5 and X4 C-HIV isolates from subject 1109, suggesting that additional mutations in the 1109-F-30 Env are required to confer T~SCM~ entry levels alike subject 1109 R5 Envs.

These results suggest that T~SCM~ are more susceptible to infection by R5 C-HIV clinical isolates than X4 strains. Future studies involving replication-competent viruses are required to more accurately quantify the susceptibility of T~SCM~ to infection by C-HIV *in vivo*. While it is important to note that T~SCM~ represent a small proportion of the total circulating CD4^+^ T-cells and their level of infection was relatively low, demonstration of their susceptibility to infection by both R5 and X4 clinical C-HIV viruses provides new information that may help inform the design and implementation of therapies that target the T~SCM~ HIV-1 reservoir, such as anti-cancer drugs that block stem cell-specific molecular pathways expressed by T~SCM~ cells \[[@CR25]\].

The susceptibility of CD4^+^ T-cell subsets to CCR5-mediated infection is maintained during progression from chronic and advanced C-HIV infection {#Sec7}
-------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether C-HIV CD4^+^ T-cell subset tropism is altered during progression from chronic to advanced C-HIV infection, we performed intra-patient statistical analysis to compare the proportion of CD4^+^ T-cell subsets infected by Envs cloned from enrolment, intermediate and final time point plasma samples (Figure [1](#Fig1){ref-type="fig"}a). Statistical significance (by Mann Whitney test) was only observed for subject 1109 between Envs from the final time point and Envs from enrolment (E) or intermediate (I) time points, where the emergence of X4 strains was associated with a significant increase in the proportion of infected CD4^+^ T-cells that were T~N~ (E p = 0.0002, I p = 0.004), and a significant decrease in the proportion of infected T~CM~ (E p = 0.0002, I p = 0.0444), T~TM~ (E p = 0.0002, I p = 0.004), T~EM~ (E p = 0.0003, I p = 0.004) and T~SCM~ (E p = 0.0263, I p = 0.0202).

Interestingly, these results suggest that as subjects 1503 and 1854 progressed from chronic to advanced C-HIV infection over a 3 year period \[[@CR12]\] (Table [1](#Tab1){ref-type="table"}), circulating R5 viruses maintained their tropism profiles for CD4^+^ T-cell subsets. While additional studies involving more C-HIV Envs isolated over longer periods of time are required to confirm these findings, our data support those from a study by Buzon et al. \[[@CR6]\], which showed that the susceptibility of T~SCM~ to infection by R5 subtype B HIV-1 is maintained during disease progression, and those from a study by Chomont et al. \[[@CR1]\], which showed that HIV-1 can persist in T~CM~ and T~TM~ of subjects who exhibit reconstitution of CD4^+^ T-cells during suppressive antiretroviral therapy.

Conclusions {#Sec8}
-----------

These findings provide new insights into the natural history of tropism alterations for CD4^+^ T-cell subsets by R5 and X4 C-HIV strains during progression from chronic to advanced stages of infection. Specifically, we showed that R5 C-HIV strains maintain their preference for infecting memory CD4^+^ T-cell subsets during later stages of C-HIV infection, whereas emergent X4 C-HIV strains preferentially target T~N~. Furthermore, by demonstrating the susceptibility of T~SCM~ to infection by C-HIV, our results highlight the potential for this subset of CD4+ T-cells to serve as a long-lived viral reservoir in individuals harboring CCR5- and CXCR4-using C-HIV viruses.
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